pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Contrave
drug
save

(bupropion hydrochloride + naltrexone) ER

Marketedupdated 3mo ago
by Currax Pharmaceuticals LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval28 co-mentions · 14 sources
  • drugbupropion hydrochloride ER14 co-mentions · 14 sources
  • tagSmall Molecule14 co-mentions · 14 sources
  • drugAUVELITY14 co-mentions · 14 sources
  • drugbupropion14 co-mentions · 14 sources
  • drugbupropion hydrochloride MR14 co-mentions · 14 sources
  • drugbupropion hydrochloride SR14 co-mentions · 14 sources
  • drugWELLBUTRIN SR14 co-mentions · 14 sources

indications

investigational
Obesity

all catalysts(0)

nothing on the calendar yet

Trials studying (bupropion hydrochloride + naltrexone) ER

  • phase4Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesityrecruitingn=40
  • phase4Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.unknownn=89
  • phase4A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgeryunknownn=18

Patent cliff

source: FDA Orange Book
first barrier falls
Jun 4, 2027
312 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Jul 2, 2034method-of-use (U-1583)US 10231964
  • Jul 2, 2034method-of-use (U-1583)US 10828294
  • Jul 2, 2034method-of-use (U-1583)US 10835527
  • Jul 2, 2034method-of-use (U-1583)US 11998542
  • Jun 25, 2033method-of-use (U-1583)US 9633575
  • Jun 5, 2033method-of-use (U-1583)US 10403170
  • Jun 5, 2033method-of-use (U-1583)US 11139056
  • Jan 13, 2032method-of-use (U-1808)US 9248123
  • Jan 10, 2031method-of-use (U-1583)US 110335434.5y
  • Feb 2, 2030method-of-use (U-1639)US 89161953.5y
  • May 29, 2029method-of-use (U-1583)US 113247412.8y
  • Feb 3, 2029formulationUS 80887862.5y
  • Nov 8, 2027method-of-use (U-1585)US 103073761.3y
  • Nov 8, 2027method-of-use (U-1585)US 120487691.3y
  • Nov 8, 2027method-of-use (U-1584)US 83187881.3y
  • Nov 8, 2027method-of-use (U-1585)US 87220851.3y
  • Nov 8, 2027method-of-use (U-1585)US 91258681.3y
  • Jun 4, 2027method-of-use (U-1639)US 9107837312d

News(0)

no news has mentioned this drug yet

brand
Contrave
generic
(bupropion hydrochloride + naltrexone)
indication
Obesity
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 30m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?